Journal of AdvancedMedical and Dental Sciences Research

Background: Typhoid fever (TF) is caused by the gram-negative bacterium Salmonella Typhi. It is also known as enteric fever. Salmonella typhi has flagellae which makes it mobile, is a gram negative non spore bearing bacteria. The present study was conducted to assess the efficacy of third generation cefixime in the management of typhoid fever. Materials & Methods: The study consisted of 92 subjects (male- 40, female-52) suffering from typhoid fever. Typhoid fever was defined by fever > 38.5°C for longer than three days and the isolation of S. typhifrom blood culture. 5 mg/kg of Cefixime po BD daily was advised in pediatric patients. Adult patients received a dose of 200 mg po, BD daily. Patients were evaluated on day 0, day 5, and day 10. The primary criteria of efficacy were absence of symptoms and signs of infection at day 10 of treatment and negative culture to S. typhiat day 10 of treatment. Results thus obtained were subjected to statistical analysis. P value < 0.05 was considered significant. Results: This study included 40 males and 52 females.). This study consisted of 46 students, 12 children, 22 housewife, 10 official and 2 others. Following strains were seen O+ (42), H+ (12), AH+ (21), BH + (11) and H, BH + (7). The difference was significant (P<0.05). In 76 cases no complications were seen. While other side effects reported were rashes (2), nausea (1), diarrhea (6), stomatitis (3), drowsiness (4). Conclusion: Cefixime is third generation antibiotic is highly effective and safe drug for treatment of typhoid. The efficacy reported was 83%. Fewer side effects were seen which can be easily manageable.
Key words: Cefixime, Salmonella typhi, Typhoid fever.